# Pharming Technologies B.V. clinical trials: 22 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials with Pharming Technologies B.V. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Pharming Technologies B.V.: 22 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/pharming-technologies-b-v

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 7, 2026 | NCT07514338 | Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease | Pharming Technologies B.V. | Phase 2 | Recruiting | Mitochondrial Diseases | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07514338) |
| May 25, 2025 | NCT06990529 | Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation | Pharming Technologies B.V. | Phase 2 | Active not recruiting | PIDs Linked to PI3K | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06990529) |
| March 26, 2025 | NCT06897358 | Leniolisib for Immune Dysregulation in CVID | Pharming Technologies B.V. | Phase 2 | Completed | Common Variable Immunodeficiency (CVID) | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06897358) |
| August 12, 2024 | NCT06549114 | Leniolisib for Immune Dysregulation in PIDs | Pharming Technologies B.V. | Phase 2 | Completed | Primary Immunodeficiency Disorders (PIDs) | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06549114) |
| February 8, 2024 | NCT06249997 | An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS | Pharming Technologies B.V. | Phase 3 | Unknown | APDS Gene Mutation | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06249997) |
| January 20, 2023 | NCT05693129 | Pediatric Patients Aged 1 to 6 Years With APDS | Pharming Technologies B.V. | Phase 3 | Active not recruiting | APDS | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05693129) |
| December 14, 2022 | NCT05650229 | Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease | Pharming Technologies B.V. | Phase 2 | Recruiting | Primary Mitochondrial Disease | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05650229) |
| June 30, 2022 | NCT05438407 | Pediatric Patients Aged 4 to 11 Years With APDS | Pharming Technologies B.V. | Phase 3 | Active not recruiting | APDS | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05438407) |
| June 3, 2021 | NCT04912141 | Prevention of Acute Kidney Injury in Patients With NSTEMI | Pharming Technologies B.V. | Phase 2 | Terminated | Non-ST Elevation Myocardial Infarction (NSTEMI) | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04912141) |
| August 28, 2020 | NCT04530136 | Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 | Pharming Technologies B.V. | Phase 2 | Completed | Confirmed Coronavirus Disease | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04530136) |
| October 5, 2018 | NCT03697187 | Patient Registry to Evaluate the Real-world Safety of Ruconest® | Pharming Technologies B.V. | Observational | Completed | Hereditary Angioedema | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03697187) |
| August 9, 2016 | NCT02859727 | Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI | Pharming Technologies B.V. | Phase 2/3 | Terminated | Activated PI3Kdelta Syndrome (APDS); PASLI Disease | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02859727) |
| September 25, 2014 | NCT02247739 | A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor | Pharming Technologies B.V. | Phase 2 | Completed | Hereditary Angioedema | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02247739) |
| July 20, 2011 | NCT01397864 | C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks | Pharming Technologies B.V. | Observational | Completed | Hereditary Angioedema | 181 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01397864) |
| May 25, 2011 | NCT01359969 | Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients | Pharming Technologies B.V. | Phase 2 | Completed | Hereditary Angioedema | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01359969) |
| August 25, 2010 | NCT01188564 | Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks | Pharming Technologies B.V. | Phase 3 | Completed | Hereditary Angioedema | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01188564) |
| December 18, 2009 | NCT01035593 | Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation | Pharming Technologies B.V. | Phase 2 | Withdrawn | Graft Rejection, Kidney Transplantation | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01035593) |
| February 26, 2009 | NCT00851409 | A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration | Pharming Technologies B.V. | Phase 2 | Completed | Genetic Disorders, Hereditary Angioedema | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00851409) |
| December 6, 2005 | NCT00262301 | Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema | Pharming Technologies B.V. | Phase 3 | Completed | Hereditary Angioedema, Angioneurotic Edema, Genetic Disorders | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00262301) |
| December 6, 2005 | NCT00262288 | Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema | Pharming Technologies B.V. | Phase 2/3 | Completed | Genetic Disorders | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00262288) |
| December 2, 2005 | NCT00261053 | Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema | Pharming Technologies B.V. | Phase 2 | Completed | Genetic Disorders | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00261053) |
| September 23, 2005 | NCT00225147 | Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema | Pharming Technologies B.V. | Phase 2/3 | Completed | Hereditary Angioedema, Angioneurotic Edema | 77 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00225147) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 2 | 12 |
| Phase 2/3 | 3 |
| Phase 3 | 5 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 13 |
| Active not recruiting | 3 |
| Recruiting | 2 |
| Terminated | 2 |
| Withdrawn | 1 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Angioedemas, Hereditary | 8 |
| Angioedema | 5 |
| Genetic Diseases, Inborn | 4 |
| Common Variable Immunodeficiency | 1 |
| Muscular Diseases | 1 |
| Muscle Weakness | 1 |
| Diabetes Mellitus | 1 |
| Primary Immunodeficiency Diseases | 1 |
| Mitochondrial Diseases | 1 |
| Non-ST Elevated Myocardial Infarction | 1 |
| Activated PI3K-delta Syndrome | 1 |
| Lymphadenopathy | 1 |
| Immunologic Deficiency Syndromes | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Podiatrists in the United States](https://specstream.ai/data/businesses/podiatrists/united-states)
- [Empanada restaurants in the United States](https://specstream.ai/data/businesses/empanada-restaurants/united-states)
- [Turkish restaurants in the United States](https://specstream.ai/data/businesses/turkish-restaurants/united-states)
- [Junk removal companies in the United States](https://specstream.ai/data/businesses/junk-removal-companies/united-states)
- [Book magazine distribution companies in the United States](https://specstream.ai/data/businesses/book-magazine-distribution-companies/united-states)
- [Process servers in the United States](https://specstream.ai/data/businesses/process-servers/united-states)
